1MG8
| NMR structure of ubiquitin-like domain in murine Parkin | Descriptor: | Parkin | Authors: | Tashiro, M, Okubo, S, Shimotakahara, S, Hatanaka, H, Yasuda, H, Kainosho, M, Yokoyama, S, Shindo, H, RIKEN Structural Genomics/Proteomics Initiative (RSGI) | Deposit date: | 2002-08-15 | Release date: | 2003-04-08 | Last modified: | 2024-05-29 | Method: | SOLUTION NMR | Cite: | NMR structure of ubiquitin-like domain in PARKIN: Gene product of familial Parkinson's disease. J.Biomol.NMR, 25, 2003
|
|
1V66
| Solution structure of human p53 binding domain of PIAS-1 | Descriptor: | Protein inhibitor of activated STAT protein 1 | Authors: | Okubo, S, Hara, F, Tsuchida, Y, Shimotakahara, S, Suzuki, S, Hatanaka, H, Yokoyama, S, Tanaka, H, Yasuda, H, Shindo, H, RIKEN Structural Genomics/Proteomics Initiative (RSGI) | Deposit date: | 2003-11-27 | Release date: | 2004-12-07 | Last modified: | 2023-12-27 | Method: | SOLUTION NMR | Cite: | NMR structure of the N-terminal domain of SUMO ligase PIAS1 and its interaction with tumor suppressor p53 and A/T-rich DNA oligomers J.Biol.Chem., 279, 2004
|
|
4LQM
| EGFR L858R in complex with PD168393 | Descriptor: | CHLORIDE ION, Epidermal growth factor receptor, N-[4-(3-BROMO-PHENYLAMINO)-QUINAZOLIN-6-YL]-ACRYLAMIDE | Authors: | Yun, C.H, Eck, M.J. | Deposit date: | 2013-07-19 | Release date: | 2014-01-15 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (2.5 Å) | Cite: | Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Sci Transl Med, 5, 2013
|
|
4LRM
| EGFR D770_N771insNPG in complex with PD168393 | Descriptor: | Epidermal growth factor receptor, N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}propanamide | Authors: | Yun, C.H, Eck, M.J. | Deposit date: | 2013-07-20 | Release date: | 2014-01-15 | Last modified: | 2023-09-20 | Method: | X-RAY DIFFRACTION (3.526 Å) | Cite: | Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Sci Transl Med, 5, 2013
|
|
7FG2
| |
7FG3
| |
7FG7
| |
5Y9T
| Crystal Structure of EGFR T790M mutant in complex with naquotinib | Descriptor: | 6-ethyl-3-[[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxy-pyrazin e-2-carboxamide, Epidermal growth factor receptor | Authors: | Mimasu, S, Tomimoto, Y, Maiko, I, Yasushi, A, Tatsuya, N. | Deposit date: | 2017-08-28 | Release date: | 2018-07-11 | Last modified: | 2023-11-22 | Method: | X-RAY DIFFRACTION (3.25 Å) | Cite: | Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, inEGFR-Mutated Non-Small Cell Lung Cancer. Mol. Cancer Ther., 17, 2018
|
|